title: Improved detection of recurrent bladder cancer using the Bard BTA stat Test.
abstract: OBJECTIVE
  To evaluate the BTA stat Test in the detection of recurrent bladder cancer.
  
  
  METHODS
  Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer.
  
  
  RESULTS
  The BTA stat Test detected 147 (67%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA stat Test 58% for detection of recurrent cancer (P < 0.001, stat versus cytology). The specificity of the BTA stat Test was 72% for benign genitourinary disease and 95% in healthy volunteers.
  
  
  CONCLUSIONS
  The BTA stat Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer.
authors.affiliation: Division of Urology, University of Texas Health Science Center, San Antonio 78284-7845, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Sarosdy
authors.forename: M A
authors.initials: MA
authors.lastname: Hudson
authors.forename: W J
authors.initials: WJ
authors.lastname: Ellis
authors.forename: M S
authors.initials: MS
authors.lastname: Soloway
authors.forename: R
authors.initials: R
authors.lastname: deVere White
authors.forename: J
authors.initials: J
authors.lastname: Sheinfeld
authors.forename: M V
authors.initials: MV
authors.lastname: Jarowenko
authors.forename: P F
authors.initials: PF
authors.lastname: Schellhammer
authors.forename: E W
authors.initials: EW
authors.lastname: Schervish
authors.forename: J V
authors.initials: JV
authors.lastname: Patel
authors.forename: G W
authors.initials: GW
authors.lastname: Chodak
authors.forename: D L
authors.initials: DL
authors.lastname: Lamm
authors.forename: R D
authors.initials: RD
authors.lastname: Johnson
authors.forename: M
authors.initials: M
authors.lastname: Henderson
authors.forename: G
authors.initials: G
authors.lastname: Adams
authors.forename: B A
authors.initials: BA
authors.lastname: Blumenstein
authors.forename: K R
authors.initials: KR
authors.lastname: Thoelke
authors.forename: R D
authors.initials: RD
authors.lastname: Pfalzgraf
authors.forename: H A
authors.initials: HA
authors.lastname: Murchison
authors.forename: S L
authors.initials: SL
authors.lastname: Brunelle
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000652:urine*; D009367:Neoplasm Staging; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000652:urine*
chemical_list: D000951:Antigens, Neoplasm